Cancer Screening

Our proprietary miRNA technology detects cancer at its earliest, most treatable stages. With minimally invasive test and accurate insights, our tests enable patients to act sooner.

GASTROClear

A pioneering blood test for the early detection of gastric (stomach) cancer.

LUNGClear

A minimally invasive blood test designed to identify lung cancer at an early stage.

Cancer Treatment Selection

We leverage advanced Next-Generation Sequencing (NGS) technology to empower patients in personalised cancer treatment selection.

APEX Tissue

A Targeted 58-Gene Profiling Test

COMPASS Tissue

A Comprehensive 1021-Gene Profiling Test

Collaborations

Our Partnerships

06 October 2025

Mirxes and Xeraya Announces A Joint Venture To Establish MyRNA Diagnostics Sdn. Bhd.

14 June 2024

Thermo Fisher Scientific, National University Hospital and Mirxes Collaborate to Enhance Access to Advanced Genomic Testing for Early Cancer Detection in Singapore

13 March 2024

PropNex Extends Free Health Screening to all 12,313 Self-Employed Salespersons, Expands Reach to Thailand Market

17 October 2022

Media Release: Launch of a new initiative to accelerate the adoption of healthtech innovations across healthcare clusters in Singapore

15 September 2021

HMT、 Mirxes と業務提携バイオマーカー探索のためのマイクロ RNA 解析サービスを開始～日本国内での独占販売契約締結～